Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Kaltura Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.53 (market cap $12.58B), while Kaltura Inc trades at $1.31 (market cap $199.08M). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 63.2× Kaltura Inc's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Kaltura Inc for 21 Days on average.
| HALO | KLTR | |
|---|---|---|
Market Cap | $12.58B | $199.08M |
Volume | 2,179,278 | 175,927 |
Sector | Health | Technology |
52-Week High | $115.22 | $1.89 |
52-Week Low | $61.63 | $1.08 |
Typical Hold Time | 1 Days | 21 Days |
Enterprise Value | $14.49B | $211.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
KLTR trades at $1.315, down 1.13% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals, with revenue stable around $181M in 2025 and a narrowing net loss of -$12.07M, though profitability remains negative. Recent news highlights AI-driven innovations and industry recognition, including a Gartner leadership mention in August 2026. Analyst sentiment is mixed with a 44% buy rating.
The outlook hinges on KLTR's ability to monetize its AI and video platform investments to achieve sustained profitability. Key risks include high debt levels, persistent negative margins, and competitive pressures. Upside potential exists if the company converts its technological accolades into revenue growth and positive earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
